Form 4: Guardant Health CFO Bell Sells Shares After RSU Vesting

Guardant Health's CFO, Michael Brian Bell, reported the acquisition of common stock through RSU vesting and subsequent sales, adjusting his beneficial ownership.

Summary

• Michael Brian Bell, Chief Financial Officer of Guardant Health, Inc. (GH), reported transactions on March 15 and March 16, 2026.
• Acquired a total of 13,790 shares of common stock through the vesting of various Restricted Stock Unit (RSU) and Performance-Based Restricted Stock Unit (PBRSU) awards on March 15, 2026, at an exercise price of $0.
• These acquisitions included 1,233 shares from an RSU award granted on May 9, 2022, 10,518 shares from a performance-based RSU award granted on June 7, 2023 (second tranche metric achieved), and 2,039 shares from an RSU award granted on June 9, 2023.
• Disposed of 7,413 shares of common stock on March 15, 2026, at a price of $85.49 to cover tax withholding obligations related to the RSU vesting.
• Sold 3,000 shares of common stock on the open market on March 16, 2026, at a weighted average price of $87.037 per share (ranging from $87.0001 to $87.1500).
• Following these transactions, Michael Brian Bell beneficially owns 43,601 shares of Guardant Health common stock directly.
• Additionally, 2,039 Restricted Stock Units from the June 9, 2023 grant remain beneficially owned as derivative securities.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive event. While there's an open market sale, it's offset by significant RSU vesting, including performance-based awards, indicating the achievement of company goals and standard executive compensation practices.

Positives

• Vesting of 13,790 Restricted Stock Units and Performance-Based Restricted Stock Units indicates achievement of performance metrics and continued tenure of the CFO.
• The performance-based RSU award (10,518 shares) vesting suggests the achievement of a 3-year performance metric.

Negatives

• The CFO sold 3,000 shares on the open market, which could be perceived as a reduction in direct exposure to the company's stock, although it's a relatively small portion of the total shares acquired.
• A significant portion (7,413 shares) was disposed of to cover tax withholding, which is a common practice but reduces the net shares retained from vesting.

Future Outlook

The filing does not contain explicit forward-looking statements or guidance, as it is a report of past insider transactions. However, the vesting schedules for the remaining RSUs indicate future potential share acquisitions upon further vesting.

Management Comments

• The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range.

Industry Context

StockSavvy.ai notes that insider transactions, particularly sales following vesting events, are common and often represent liquidity events for executives rather than a signal of negative sentiment towards the company's future. The achievement of performance metrics for the PBRSUs suggests operational success within Guardant Health's specific segment of the healthcare diagnostics industry.

Comparison to Industry Standards

• The practice of executives selling shares to cover tax obligations upon RSU vesting is standard across industries and aligns with typical compensation structures for publicly traded companies.
• Open market sales by insiders are a routine part of executive compensation and personal financial planning, often executed under Rule 10b5-1 plans to avoid accusations of trading on material non-public information. This filing indicates a transaction made pursuant to such a plan.
• The vesting of performance-based RSUs, as seen with Guardant Health's CFO, is a common incentive mechanism in the biotech and diagnostics sector, linking executive compensation directly to company performance metrics, similar to practices at peers like Illumina or Exact Sciences.

Stakeholder Impact

• Shareholders: The sale of shares by a CFO could be interpreted in various ways, but the context of RSU vesting suggests it's part of a compensation plan. The achievement of performance metrics for PBRSUs is generally positive for shareholders.
• Employees: The vesting of RSUs and PBRSUs reflects standard executive compensation practices, which can influence overall employee morale and retention strategies.

Next Steps

• Remaining 67% of the RSU award granted on June 9, 2023, will vest in equal quarterly installments over the remaining two-year period after June 15, 2024.

Key Dates

Recommendation

This Form 4 filing details routine insider transactions, primarily the vesting of restricted stock units and subsequent sales for tax obligations and personal liquidity. While the CFO sold a portion of shares, the underlying vesting events, including performance-based awards, suggest the company is meeting its internal targets. These transactions do not provide new fundamental information to warrant a change in investment thesis, thus a 'hold' recommendation is appropriate for existing investors.

Keywords

Guardant Health, GH, Michael Brian Bell, CFO, Insider Trading, Form 4, Restricted Stock Units, RSU, Performance-Based RSU, Stock Sale, Beneficial Ownership